Infectious Disease Therapeutics Market by Drug class, disease indication, Distribution channel and Geography. key Players are GlaxoSmithKline Plc (U.K.), Johnson & Johnson Services, Inc. (U.S.), Merck & Co, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG. (S

Precision Business Insights (PBI) in its report titled “Infectious Disease Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The infectious disease therapeutics market size was accounted for US$ XX Mn in 2018 and anticipated to account for US$ XX Mn by 2025. Infectious diseases transmitted from one individual to other individual will create a demand for the infectious disease therapeutics market. Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of infectious disease therapeutics market.

Infectious disease therapeutic market segmented on the basis of drug class, disease condition and distribution channel.

Hepatitis Segment Expected to Dominate the Market

Based on disease condition, the infectious disease therapeutics market is segmented into influenza, AIDS/HIV, hepatitis, malaria, TB and others. Hepatitis segment is expected to dominate the market rising prevalence of hepatitis, increasing clinical trial activities for the launch of new drugs, and growing number of initiatives to increase the adoption of drugs.

North America, Accounts for Major Revenue Share for Infectious Disease Therapeutic Market

Precision Business Insights (PBI), infectious disease therapeutic market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional analysis, North America accounted for major revenue share owing to high prevalence rates of infectious diseases and rise in ageing population. According to scientific data from Princeton University 2015, rising trend in consumption of anti-infective has increased in BRICS nation. In the last few years, there was an increase in use of antibiotics in Asian countries like India and China and some parts of Africa.

Read more Insights at https://precisionbusinessinsights.com/market-reports/global-infectious-disease-therapeutics-market/

Strategic Acquisitions and U.S. FDA Approval Play Vital Role in Infectious Disease Therapeutics Market

Approval from U.S. FDA and market acquisitions play an important role in the development of the infectious disease therapeutics market. For instance, in July 2017, Gilead’s “vosevi” oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus. In August 2016, Pfizer acquired AstraZeneca’s late-stage small molecule anti-infectives business for development and commercialization outside the U.S.

Request Sample Brochure of the Report at https://precisionbusinessinsights.com/request-sample?product_id=15573

Key players in the market include GlaxoSmithKline Plc (U.K.), Johnson & Johnson Services, Inc. (U.S.), Merck & Co, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG. (Switzerland), AbbVie Inc. (U.S.), Astellas Pharma Inc. (Japan), AstraZeneca (U.K.), Auritec Pharmaceuticals Inc. (U.S.), Bayer AG (Germany), Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.), Chimerix Inc. (U.S.), Eli Lilly and Company (U.S.), Isis Pharmaceuticals (U.S.), Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan), Sanofi S.A. (France) and Gilead Sciences (U.S.) to name a few.

Detailed Segmentation

By Drug Class

o Anti-Bacterial
o Anti-Viral
o Anti-Parasite
o Anti-Fungal
o Others

By Disease Condition

o HIV/AIDS
o Influenza
o Hepatitis
o Malaria
o TB
o Others

By Distribution Channel

o Hospital Pharmacy
o Retail Pharmacy
o Others

Geography

o North America
 U.S.
 Canada
o Europe
 Germany
 UK
 France
 Russia
 Spain
 Italy
 Rest of Europe
o Asia-Pacific
 China
 Japan
 India
 ASEAN
 Rest of Asia Pacific
o Latin America
 Brazil
 Mexico
 Argentina
 Chile
 Rest of Latin America
o Middle East and Africa
 South Africa
 Gulf Cooperation Council Countries(GCC)
 Rest of MEA

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact us
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com

This release was published on openPR.